TipRanks
Oppenheimer: These two stocks may double or even more
This is the final countdown. The U.S. presidential election is only two weeks away. The pressure of the election year is going on all over Wall Street, but one expert believes that no matter what the outcome is, opportunities may arise. Oppenheimer’s chief investment strategist John Stoltzfuchs pointed out to the White House: “The market seems to be sending a signal, no matter how loud the two sides are, no matter which side wins, after the day of the inauguration in January 2021, Some form of investment opportunity can overcome risk.” He added: “In our experience, uncertainty usually brings opportunities, and the perception of “certainty” tends to make people complacent.” As for the third quarter In the profitable season, its upside has been surprising. Although it is too early to say how this season will proceed, Stoltzfors said that “everything has been great so far.” Data from last weekend showed that 84% of the companies that had been reported exceeded expectations. 82% of companies exceeded their revenue expectations for the quarter. Considering Stoltzfus’ prospects, Oppenheimer analysts are finalizing two low-priced stocks and point out that they may double or more next year. Using the TipRanks database, we found that the rest of Wall Street is also involved, because everyone has a “strong buy” consensus rating. NeuBaseTherapeutics (NBSE) develops next-generation gene silencing therapies through its flexible and highly specific approach. Synthesizing antisense oligonucleotides, NeuBase Therapeutics hopes to improve the lives of patients everywhere. Based on the advantages of its platform, Oppenheimer believes that there may be major changes. Company analyst Hartaj Singh focused on the company’s peptide nucleic acid (PNA) AnTisense oligonucleotide (PATrOL) platform, which enables rapid drug design to treat various medical abnormalities and overcomes the first generation of antisense oligonucleotides. The technical limitations of acid (ASO), systemic delivery (IV), blood-brain barrier penetration, increased cell permeability, access to genomic sites and secondary RNA structure, and development of highly selective therapies. In view of the great potential of ASO in treating diseases, the current first-generation therapy field has created “obstacles” for companies like NBSE. The technical advantages of ASO through its PATrOL platform may lead to higher-risk therapy / Singh explained. In addition, the long tail redistribution of NBSE’s PNA may have a significant impact on the dosing schedule of t. These agents (maybe weeks to months). Singh mentioned: ”Combined with the enhancement of the target’s medicability through PNA, we will continue to attach great importance to the potential of the PATrOL platform and, as always, focus on the safety of such new drugs.” On 2020 Six months later, “helps to further verify the effectiveness” on this platform, the company will continue to maintain its leading Huntington’s disease (HD) drug candidate NT0100 development trajectory. The selection of additional preclinical results and candidate drugs will be completed by YE20. “As the delivery of treatments and their penetration into deep brain structures is still critical for diseases such as HD, we encourage more PD data from preclinical models (Q4 2020)… although These pre-clinical NHP PK data have early nature and in vitro PD data. We believe that they fully verify that NeuBase has truly developed a “better mousetrap” and a way to distinguish its technology from traditional ASO.” These features can be found in Inherited throughout the PNA class. Therefore, Singh has high hopes for the HD and myotonic dystrophy (DM1) product NT0200. DM1 is about six months behind the HD plan. After the candidates are selected in 1H21, the research to enable IND can be initiated. Everything NBSE has done has prompted Singh to maintain its outperform (ie, buy) rating. While calling options, he maintained his target stock price at $17, implying a 104% upside potential. (To view Singer’s track record, click here) Do other analysts agree? they are. In the last three months, only 4 exact “buy” ratings have been published. Therefore, the message is clear: NBSE is a strong buy. Taking into account the average price target of $16.50, the stock price may surge 97% next year. (See NBSE stock analysis on TipRanks). Prevail Therapeutics (PRVL) Next, we have Prevail Therapeutics, which is developing improved gene therapies for Parkinson’s disease and other neurodegenerative diseases. After making an impressive update to the progress of the product line, Oppenheimer expressed satisfaction. GBA1 mutation (PD-GBA). This mutation affects approximately 9% of all PD patients in the United States. In the trial, the patient included two patients. Preliminary data showed that CSF GCase activity normalized in the third month from a level that was not detected at baseline. Olsen believes that this strongly implies clinical improvement. It should be noted that there was a serious adverse event (SAE) in the 3rd month, which is probably related to the immune response to the AAV9 capsid, which has been resolved. However, analysts believe that the immune response of AAV9 gene therapy is normal and short-lived. In addition, PRVL submitted a protocol amendment to the PROPEL trial, and recruitment is expected to continue in 2H20. The company hopes to change the design to an open-label study for 12 patients, including 12 patients, and plans to optimize the immunosuppressive program to save on steroid use. To this end, two-month safety and biomarker data for some patients are scheduled to be released in mid-2021. If the therapy is finally approved for this indication, Olson believes that risk-adjusted sales in 2035 may reach $8 billion. In addition, in Gaucher’s disease, CSF GCase activity in the fourth month also returned to normal from the baseline undetected level (GD2). Patients use PR001 in a compassionate use program. This rare hereditary lysosomal disease is also caused by the autosomal recessive inheritance of the GBA1 gene. Olsen believes that this result provides a positive basis for the 1/2 PROVIDE study of GD2, which began in 2H20. “Because GD2 is a rare disease that affects babies and leads to a very short life expectancy, we believe that compared with other GBA1-related indications, GD2 has a shorter regulatory pathway. We estimate that, Due to the lack of treatment for GD2, if clinically successful, PR001 approval may be achieved in 2024.” More importantly, PR006’s Phase 1/2 PROCLAIM study (its treatment for GRN frontotemporal dementia (GRN-FTD)) ) It is expected to start in 2H20, and it is expected that the biomarkers will be read from some patients for two months at the end of 2020 or later. In view of all the above, Olsen said: “We think the stock price is at an attractive entry point. And PRVL still has sufficient capital, with 131 million US dollars in cash, which can provide funds to enter 1H22.” Then, it is not surprising that Olsen stayed with the Bulls. In addition to assigning an “outperform” (ie, “buy”) rating, he also set a target price of $25 for the stock. If this goal is achieved in the next twelve months, investors may get 156% of the return. (To view Olsen’s track record, click here.) In short, other analysts are responding to Olsen’s views. Five buys, no hold or sells add up to get a strong buy consensus rating. The average target price is US$23.25, and the upside potential is 139%. (See PRVL stock analysis on TipRanks) To find a good idea for stock trading at attractive valuations, please visit TipRanks’ Best Buys to Buy, a newly launched tool that can convert all TipRanks stocks Combine insights. Those featured analysts. The content is for reference only. Before making any investment, it is very important to conduct your own analysis.
#ServiceNow #named #leader #stream #management #solutions #independent #research #company